A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Tumor Interventions: Drug: Talazoparib; Drug: ASTX727 Sponsors: Kathy Miller; Pfizer; Astex Pharmaceuticals, Inc.; Van Andel Institute Stand Up to Cancer Team Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials